top of page
Dynamic Drug Advancement Limited | Durham Institute of Respirology
About the Trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Mechanism of Action:
IgG1 mAb OX40/OX40L Inhibitor
Duration of Study
Phase
2
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Nusrat Jahan
bottom of page